Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Staphylococcus aureus is a common cause of native valve infective endocarditis (IE). Rifampin is often added to traditional therapy for the management of serious S. aureus infections. There are no large, prospective studies documenting the safety and efficacy of adjunctive therapy with rifampin for treatment of native valve S. aureus IE. We reviewed all cases of definite native valve S. aureus IE confirmed by modified Duke criteria in a large urban hospital between 1 January 2004 and 31 December 2005. A retrospective cohort analysis was used to assess the impact of the addition of rifampin to standard therapy. There were 42 cases of S. aureus IE treated with the addition of rifampin and 42 controls. Cases received a median of 20 days of rifampin (range, 14 to 48 days). Rifampin-resistant S. aureus isolates developed in nine cases who received rifampin before clearance of bacteremia (56%), while significant hepatic transaminase elevations also occurred in nine cases, all of whom had hepatitis C infection. Unrecognized significant drug-drug interactions with rifampin occurred frequently (52%). Cases were more likely to have a longer duration of bacteremia (5.2 versus 2.1 days; P < 0.001) and were less likely to survive (79% versus 95%; P = 0.048) than controls. Our results suggest that the potential for hepatotoxicity, drug-drug interactions, and the emergence of resistant S. aureus isolates warrants a careful risk-benefit assessment before adding rifampin to standard antibiotic treatment of native valve S. aureus IE until further clinical studies are performed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, use of rifampin as adjunct therapy for S aureus NVE has been associated with higher rates of adverse events (primarily hepatotoxicity) and a significantly lower survival rate.162”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 4×
“All cases and controls had definite S. aureus IE based on the modified Duke criteria ( 19 ).”
MethodInfluentialKlevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726 · cited 1×
“While S. aureus IE has long been associated with significant morbidity and mortality (8, 23, 25), its management is now further complicated by the rising incidence of methicillin-resistant S. aureus (MRSA) strains causing disease ( 16 ), as well as the limited treatment options for MRSA (17, 22).”
BackgroundBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459 · cited 1×
“003 Right and left sided 3 (7) 9 (21) 0.”
Self-citationStaphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174 · cited 2×
“aureus IE has long been associated with significant morbidity and mortality (8, 23, 25), its management is now further complicated by the rising incidence of methicillin-resistant S.”
BackgroundResistance to Antibiotics Mediated by Target Alterations
Spratt, B. G. (1994) · Science · doi:10.1126/science.8153626 · Cited by 674 · cited 2×
“aureus infections (15, 28), and it has recently been shown at the genetic level to occur after only a single dose of rifampin in a patient with MRSA endocarditis (24).”
BackgroundLevine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577 · cited 4×
“(18) also showed that rifampin plus vancomycin was no better than vancomycin alone for treatment of MRSA IE, though that trial was likely underpowered to detect a true difference.”
BackgroundInfluentialMwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538 · cited 2×
“aureus infections (15, 28), and it has recently been shown at the genetic level to occur after only a single dose of rifampin in a patient with MRSA endocarditis (24).”
BackgroundHowden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484 · cited 1×
“(%) Central nervous system 14 (33) 6 (14) 0.”
Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling
Kizana, E., Ginn, S. L., Allen, D. G., Ross, D. L., & Alexander, I. E. (2005) · Circulation · doi:10.1161/01.cir.0000153812.64956.ef · Cited by 382
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
“Although the level of evidence is poor, adding rifampin to the treatment of staphylococcal PVE is standard practice, although treatment may be associated with microbial resistance, hepatotoxicity and drug interactions.(164)”
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“aureus endocarditis did not improve outcomes but was associated with hepatic adverse effects, drug interactions, and the emergence of resistance [173].”
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“ated with higher rates of adverse events (primarily hepatotoxicity) and a significantly lower survival rate.(162) Thus, routine”
BackgroundGuidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Gould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Management Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis
Lee, J. Y. H., Monk, I. R., Gonçalves da Silva, A., Seemann, T., Chua, K. Y. L., Kearns, A., Hill, R., Woodford, N., Bartels, M. D., Strommenger, B., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0230-7 · Cited by 299
Clinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Rifampin Combination Therapy for Nonmycobacterial Infections
Forrest, G. N., & Tamura, K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-09 · Cited by 242
Self-citationMoellering, R. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr437 · Cited by 236
Zimmerli, W., & Sendi, P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01746-18 · Cited by 216
Abdul-Aziz, M., Lipman, J., Mouton, J., Hope, W., & Roberts, J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398490 · Cited by 188
Endocarditis and Intravascular Infections
Fowler, V. G., Scheld, W. M., & Bayer, A. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00082-5 · Cited by 153
Deresinski, S. C. (2009) · Clinical Infectious Diseases · doi:10.1086/605572 · Cited by 156
Native valve right sided infective endocarditis
Akinosoglou, K., Apostolakis, E. E., Marangos, M. N., & Pasvol, G. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.010 · Cited by 137
“In addition, there is increased hepatic toxicity with rifampicin in IDUs with concomitant HCV infection [90].”
BackgroundLegout, L., Sarraz-Bournet, B., D’Élia, P., Devos, P., Pasquet, A., Caillaux, M., Wallet, F., Yazdanpanah, Y., Senneville, É., Haulon, S., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03618.x · Cited by 128
“On the basis of our experience in managing valvular prostheses and orthopaedic infections [22–28], we feel that the use of antimicrobial agents such as rifampin, quinolones or daptomycin (especially for infection caused by Gram-positive cocci) [29,30], combined with optimal surgical treatment and followed by long-term…”
BackgroundComparative Effectiveness of Clostridium difficile Treatments: A Systematic Review
Drekonja, D. M., Butler, M., MacDonald, R., Bliss, D., Filice, G. A., Rector, T. S., & Wilt, T. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-12-201112200-00007 · Cited by 123
Nguyen, H. M., & Graber, C. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp377 · Cited by 132
Revest, M., Camou, F., Senneville, E., Caillon, J., Laurent, F. J., Calvet, B., Feugier, P., Batt, M., & Chidiac, C. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.04.014 · Cited by 124
“Its prescription as monotherapy is strongly discouraged, as is its use in bacteraemic patients [98], owing to the rapid emergence of a resistant strain of bacteria.”
BackgroundCombination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections
van Hal, S. J., Tong, S. Y. C., & Davis, J. S. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1396906 · Cited by 118
Karlsen, Ø. E., Borgen, P. O., Bragnes, B., Figved, W., Grøgaard, B., Rydinge, J., Sandberg, L., Snorrason, F., Wangen, H., Witsø, E., et al. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01877-2 · Cited by 103
Beldman, M., Löwik, C., Soriano, À., Albiach, L., Zijlstra, W. P., Knobben, B. A. S., Jutte, P. C., de Sousa, R. J. G., Carvalho, A., Goswami, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab426 · Cited by 98
Galar, A., Weil, A. A., Dudzinski, D. M., Muñóz, P., & Siedner, M. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-18 · Cited by 103
“pedic hardware, prostheses, or vascular grafts (143).”
Management of methicillin-resistant Staphylococcus aureus infections
Garau, J., Bouza, E., Chastre, J. E., Gudiol, F., & Harbarth, S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02701.x · Cited by 100
“rifampin, the combination may even be antagonistic, and resistance may develop during therapy [35,36].”
BackgroundIntermittent antibiotic treatment of bacterial biofilms favors the rapid evolution of resistance
Usui, M., Yoshii, Y., Thiriet-Rupert, S., Ghigo, J., & Beloin, C. (2023) · Communications Biology · doi:10.1038/s42003-023-04601-y · Cited by 89
Current Challenges in the Management of Infective Endocarditis
Cuervo, G., Escrihuela-Vidal, F., Gudiol, C., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641243 · Cited by 89
“aureus is discouraged (136), but could be useful in PVE, given its potent activity in infections involving biofilms.”
BackgroundAminoglycosides for infective endocarditis: time to say goodbye?
Lebeaux, D., Fernández‐Hidalgo, N., Pilmis, B., Tattevin, P., & Mainardi, J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.017 · Cited by 75
Methicillin-Resistant Staphylococcus Aureus Infections
Taylor, A. R. (2013) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2013.06.002 · Cited by 83
Staphylococcus aureus Internalized by Skin Keratinocytes Evade Antibiotic Killing
Kindi, A. A., Alkahtani, A. M., Nalubega, M., Chami, C. E., O’Neill, C. A., Arkwright, P. D., & Pennock, J. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02242 · Cited by 65
“Despite its efficacy, solitary use of rifampicin rapidly leads to antibiotic resistance (Riedel et al., 2008; Thwaites et al., 2018).”
BackgroundLê, H., Arnoult, C., Dé, E., Schapman, D., Galas, L., Cerf, D. L., & Karakasyan, C. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.1c00082 · Cited by 65
Rieg, S., Joost, I., Weiß, V., Peyerl‐Hoffmann, G., Schneider, C., Hellmich, M., Seifert, H., Kern, W. V., & Kaasch, A. J. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.08.026 · Cited by 62
Entenza, J. M., Giddey, M., Vouillamoz, J., & Moreillon, P. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.022 · Cited by 61
Optimizing combination rifampin therapy for staphylococcal osteoarticular infections
Coiffier, G., Albert, J.-D., Arvieux, C., & Guggenbuhl, P. (2013) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.09.008 · Cited by 55
Green synthesis of rifampicin-loaded copper nanoparticles with enhanced antimicrobial activity
Woźniak-Budych, M., Przysiecka, Ł., Langer, K., Peplińska, B., Jarek, M., Wiesner, M., Nowaczyk, G., & Jurga, S. (2017) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-017-5857-z · Cited by 55
Wu, X., Zhang, J.-H., Feng, Z.-S., Chen, W., Zhang, F., & Li, Y. (2019) · The Analyst · doi:10.1039/c9an01994d · Cited by 53
Epidemiology of Staphylococcus aureus in Italy: First nationwide survey, 2012
Campanile, F., Bongiorno, D., Perez, M., Mongelli, G., Sessa, L., Benvenuto, S., Gona, F., Varaldo, P. E., & Stefani, S. (2015) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2015.06.006 · Cited by 58
“This is of great concern as the use of rifampicin has been reevaluated in the treatment of bacteraemia and endocarditis caused by MRSA, in combination with vancomycin and/or daptomycin [22].”
BackgroundDryden, M., Andrašević, A. T., Bassetti, M., Bouza, E., Chastre, J. E., Cornaglia, G., Esposito, S., French, G. L., Giamarellou, H., Gyssens, I. C., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03135.x · Cited by 57
“aureus isolates [96].”
Methicillin-resistant Staphylococcus aureus antibiotic resistance and virulence
Xia, J., Gao, J., Kokudo, N., Hasegawa, K., & Tang, W. (2013) · BioScience Trends · doi:10.5582/bst.2013.v7.3.113 · Cited by 58
“bacteraemia and endocarditis with both vancomycin and rifampicin (41-43).”
Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?
Renz, N., Trampuž, A., & Zimmerli, W. (2021) · Antibiotics · doi:10.3390/antibiotics10020165 · Cited by 48
Bacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus
Bergin, S. P., Holland, T. L., Fowler, V. G., & Tong, S. Y. C. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_5001 · Cited by 51
[Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus].
Mensa, J., Barberán, J., Llinares, P., Picazo, J. J., Bouza, E., Álvarez-Lerma, F., Borges, M. D. S., Serrano, R., León, C., Guirao, X., et al. (2008) · PubMed · Cited by 66
Hagihara, M., Crandon, J. L., & Nicolau, D. P. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.632631 · Cited by 51
“A retrospective cohort analysis to access the impact of the addition of rifampin to standard therapy of native valve infective endocarditis showed that significant drug interactions with rifampin occurred in more than 50% of the cases (52%), most commonly with methadone, warfarin, HIV protease inhibitors, antifungals…”
BackgroundManagement of Gram-Positive Coccal Bacteremia and Hemodialysis
Fitzgibbons, L. N., Puls, D. L., MacKay, K., & Forrest, G. N. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.12.013 · Cited by 47
Self-citationS. aureus endocarditis: Clinical aspects and experimental approaches
Hoerr, V., Franz, M., Pletz, M. W., Diab, M., Niemann, S., Faber, C., Doenst, T., Schulze, P. C., Deinhardt‐Emmer, S., & Löffler, B. (2018) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2018.02.004 · Cited by 51
A review of current treatment strategies for infective endocarditis
Paz, D. L., Lakbar, I., & Tattevin, P. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1822165 · Cited by 44
Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 63
“aureus endocarditis significantly prolonged the duration of bacteremia, caused hepatotoxicity and drug interactions, and led to the emergence of resistant strains [45].”
BackgroundRyder, J. H., Tong, S. Y. C., Gallagher, J. C., McDonald, E. G., Thevarajan, I., Lee, T. C., & Cortes-Penfield, N. W. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac583 · Cited by 37
Grillo, S., Cuervo, G., Carratalà, J., Grau, I., Pallarés, N., Tebé, C., Guillem, L., Murillo, Ó., Ardanuy, C., Domínguez, M. Á., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz018 · Cited by 38
“Although β-lactams in combination with rifampin have been demonstrated to display in vitro synergistic activity, better antibiofilm activity, improved intracellular penetration, and rapid bactericidal activity, they do not increase survival rates in bacteremia and are also associated with hepatotoxicity [9, 10].”
BackgroundAudit of antibiotic therapy used in 66 cases of endocarditis
Demonchy, É., Dellamonica, P., Roger, P., Bernard, E., Cua, É., & Pulcini, C. (2011) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2011.08.003 · Cited by 37
New Perspectives of Infections in Cardiovascular Disease
Fong, I. W. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788166679 · Cited by 36
Bot, A. L., Lecomte, R., Gazeau, P., Bénézit, F., Arvieux, C., Ansart, S., Boutoille, D., Berre, R. L., Chabanne, C., Lesouhaitier, M., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1040 · Cited by 33
“Rifampin-related liver toxicity is not rare, mostly affects patients with underlying liver diseases (22), and may lead to treatment discontinuation in as much as 30% of patients (16,17), as in our cohort.”
BackgroundSalem, A. H., Elkhatib, W. F., & Noreddin, A. M. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01183.x · Cited by 36
“treatment of MRSA endocarditis with a slight trend in favour of vancomycin monotherapy.([16,22,24,49]) A limitation of our study is the use of one MRSA strain, which limits the generalizability of the results.”
BackgroundRole of rifampin for the treatment of bacterial infections other than mycobacteriosis
Lee, C.-Y., Huang, C., Lu, P., Ko, W., Chen, Y., & Hsueh, P. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.08.013 · Cited by 33
Morrisette, T., Alosaimy, S., Abdul‐Mutakabbir, J. C., Kebriaei, R., & Rybak, M. J. (2020) · Antibiotics · doi:10.3390/antibiotics9110762 · Cited by 33
“It is important to note that VAN MICs were not reported [84].”
BackgroundLegout, L., D’Elia, P., Sarraz-Bournet, B., Rouyer, C., Massongo, M., Valette, M., Leroy, O., Haulon, S., & Senneville, É. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-228 · Cited by 35
Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteraemia: a systematic review
Russell, C. D., McLean, A. L., Saunders, C., & Laurenson, I. F. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.072280-0 · Cited by 33
Ma, H., Cheng, J., Peng, L., Gao, Y., Zhang, G., & Luo, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230383 · Cited by 33
“Details regarding daily dose and duration of rifampin therapy were given in six studies (ranged from 450 to 1200mg via intravenously or orally) but missed in one [26].”
MethodResultTremblay, S., Lau, T. T. Y., & Ensom, M. H. H. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r726 · Cited by 31
MRSA Infections: From Classical Treatment to Suicide Drugs
Drebes, J., Künz, M., Pereira, C. A., Betzel, C., & Wrenger, C. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867320666131119122520 · Cited by 33
Invasive community-associated MRSA infections: epidemiology and antimicrobial management
Pichereau, S., & Rose, W. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511614 · Cited by 32
“Also, resistance to rifampicin in a retrospective study developed in > 50% of cases in which it was added before bacteremia cleared [111].”
BackgroundElgrail, M. M., Chen, E., Shaffer, M. G., Srinivasa, V. R., Griffith, M. P., Mustapha, M. M., Shields, R. K., Tyne, D. V., & Culyba, M. J. (2022) · Infection and Immunity · doi:10.1128/iai.00001-22 · Cited by 30
“Rifampin resistance mutations are known to evolve rapidly in rpoB after drug exposure (27, 28), and resistance was detected in isolates from both patients (Data Set S2).”
Endocarditis and Intravascular Infections
Fowler, V. G., Scheld, W. M., & Bayer, A. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00077-1 · Cited by 40
Tabaja, H., Chesdachai, S., Shah, A., Stevens, R. W., DeMartino, R. R., Erben, Y., Wilson, W. R., Baddour, L. M., & DeSimone, D. C. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae150 · Cited by 27
Burden of Rifampicin- and Methicillin-Resistant Staphylococcus aureus in Italy
Bongiorno, D., Mongelli, G., Stefani, S., & Campanile, F. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0299 · Cited by 31
“23 All 50 RIF-R isolates belonged to the major MDR-MRSA clones circulating in Italy, with a higher prevalence of ST228-SCC mec I ( n = 22, 44%), as already reported by HA-MRSA epidemiology, in Italy.”
Bessesen, M. T., Doros, G. D., Henrie, A. M., Harrington, K. M., Hermos, J. A., Bonomo, R. A., Ferguson, R. E., Huang, G. D., & Brown, S. T. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-019-4751-3 · Cited by 28
El catéter periférico: el gran olvidado de la infección nosocomial
Capdevila, J. A. (2013) · Revista española de quimioterapia. Suplemento · Cited by 59
Thwaites, G. E., Auckland, C., Barlow, G. D., Cunningham, R., Davies, G., Edgeworth, J. D., Greig, J. M., Hopkins, S., Jeyaratnam, D., Jenkins, N., et al. (2012) · Trials · doi:10.1186/1745-6215-13-241 · Cited by 26
“aureus infections [22-24] to 20-40% of patients in other smaller case series [25-27].”
BackgroundHabib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., Antunes, M. J., Thilén, U. J., Lekakis, J. P., et al. (2009) · Revista Española de Cardiología · doi:10.1016/s0300-8932(09)73131-8 · Cited by 44
Forsblom, E., Ruotsalainen, E., & Järvinen, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122824 · Cited by 26
Yusuf, E., Bramer, W. M., & Anas, A. A. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107015 · Cited by 24
Shrestha, N. K. M., Shah, S. Y., Wang, H., Hussain, S. T., Pettersson, G., Nowacki, A. S., & Gordon, S. M. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.11.015 · Cited by 25
“aureus [24, 26], and it is about 10 times those of studies that showed beneficial effects of rifampin in patients with orthopedic prosthetic infections [10–12].”
BackgroundResultCroes, S., Beisser, P. S., Neef, C., Bruggeman, C. A., & Stobberingh, E. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-09 · Cited by 23
“Exposure to combination therapy including rifampin frequently results in the emergence of rifampin-resistant subpopulations, which might hinder clearance of the infection (25).”
BackgroundNew therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus
Bouza, E. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03091.x · Cited by 29
Choudhury, I., Han, H., Manthani, K., Gandhi, S. A., & Dabhi, R. (2020) · Cureus · doi:10.7759/cureus.9000 · Cited by 22
Grillo, S., Puig‐Asensio, M., Schweizer, M. L., Cuervo, G., Oriol, I., Pujol, M., & Carratalà, J. (2022) · Microorganisms · doi:10.3390/microorganisms10050848 · Cited by 22
Ahmad, N. M., & Rojtman, A. D. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m665 · Cited by 22
Moing, V. L., Bonnet, É., Cattoir, V., Chirouze, C., Deconinck, L., Duval, X., Hoen, B., Issa, N., Lecomte, R., Tattevin, P., et al. (2024) · Infectious Diseases Now · doi:10.1016/j.idnow.2024.105011 · Cited by 19
Thwaites, G. E., Scarborough, M., Szubert, A. J., Saramago, P., Soares, M. O., Bostock, J., Nsutebu, E., Tilley, R. F., Cunningham, R., Greig, J. M., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22590 · Cited by 18
Giulieri, S. G., Holmes, N. E., Stinear, T. P., & Howden, B. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1233815 · Cited by 17
“addition of rifampicin to other drug therapies (often vancomycin or daptomycin) in difficult to treat infections such as endocarditis is controversial [65,67].”
BackgroundZein, S. E., Berbari, E. F., Passerini, M., Petri, F., Maamari, J., Murad, M. H., Sendi, P., & Tande, A. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad560 · Cited by 16
Tan, C., Lai, C., Liao, C., Lin, S., Huang, Y., & Hsueh, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.01.018 · Cited by 16
Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST
Holland, T. L., & Fowler, V. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)33294-4 · Cited by 13
Lee, Y., Kim, S. S., Choi, S., Bae, C.-J., Oh, T. H., Kim, S. E., Kim, U. J., Kang, S., Jung, S., & Park, K. H. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.12.005 · Cited by 13
Gold, H. S., & Pillai, S. K. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.10.008 · Cited by 17
Staphylococcus lugdunensisbacteremia and endocarditis treated with cefazolin and rifampin
Duhon, B. M., Dallas, S. D., Velasquez, S. A. T., & Hand, E. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140498 · Cited by 10
Yavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Maslow, M. J., & Portal‐Celhay, C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00027-8 · Cited by 12
Lee, J. Y. H., & Howden, B. P. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1041924 · Cited by 9
Infective Endocarditis: New Challenges in a Classic Disease
Cuervo, G., Meneses, M. H., Falces, C., Quintana, E., Vidal, B., Marco, F., Perissinotti, A., Carratalà, J., Miró, J. M., & The Hospital Clinic and the Hospital of Bellvitge Endocarditis Team Investigators (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1742482 · Cited by 6
Davis, K. P., McDermott, L. A., Snydman, D. R., & Aldridge, B. B. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00976-24 · Cited by 6
“These recommendations are also supported by a retrospective cohort analysis for infective endocarditis (45) due to S. aureus .”
BackgroundEvaluation of antibiotic therapy following valve replacement for native valve endocarditis
Fadel, H. J., Tleyjeh, I. M., Steckelberg, J. M., Wilson, W. R., & Baddour, L. M. (2009) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0784-7 · Cited by 6
“More recent work [12] included a cohort of 42 patients with native valve endocarditis due to S.”
MethodStaphylococcus-aureus-Blutstrominfektion – eine interdisziplinäre Herausforderung
Hagel, S., Kaasch, A. J., Weis, S., Seifert, H., Pletz, M. W., & Rieg, S. (2019) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-0756-8263 · Cited by 8
“Riedel et al. (2008) [34] Rifampicin retrospektive Kohortenstudie, monozentrisch 84 Patienten mit S.-aureus-Nativklappen-Endokarditis 42 Patienten mit Rifampicin-KT (Median 20 Tage) 30-Tage-Überleben (KT vs. MT): 79 vs. 95%; p = 0,048 chirurgische Sanierung (KT vs. MT): 1 vs. 5%; p = 0,03…”
BackgroundRamsey, K. M., & Mazer, M. A. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c0dc8f · Cited by 6
Prats-Peinado, L., Fernández‐Fernández, T., Márquez-Gómez, M., Matas-Díaz, J. A., Sánchez-Somolinos, M., de la Villa, S., Vaquero, J., & Sanz-Ruíz, P. (2024) · Antibiotics · doi:10.3390/antibiotics13060538 · Cited by 5
“Based on previous data, withdrawal of rifampicin due to adverse events ranges from 14% to 50% [41].”
MethodKrizsán, G., Sallai, I., Veres, D. S., Prinz, G., Kovács, M., & Skaliczki, G. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04091-y · Cited by 5
“However, resistance may develop even when rifampicin is used in combination, especially in the presence of certain predisposing factors including postoperative drainage, fistula, open wound and abscess [8].”
BackgroundLeung, Y. K. S., Ledergerber, B., Eberhard, N., Mestres, C. A., Rančić, Z., Zimmermann, A., Zbinden, R., Brugger, S. D., Zinkernagel, A. S., Hasse, B. K., et al. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab041 · Cited by 5
Metadata
- Authors
- Riedel, D. J., Weekes, E., & Forrest, G. N.
- Affiliations
- University of Maryland, Baltimore (US)
- University of Maryland Medical Center (US)
- Corresponding author
- Riedel, David J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-07
- Volume
- 52
- Issue
- 7
- Pages
- 2463-2467
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2443910
- OpenAlex
- W2145616988
- Cited by
- 136
- References
- 33
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 8 · 2022: 4 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 14 · 2014: 5 · 2013: 10 · 2012: 6
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- rifampicin, native valve endocarditis, Staphylococcus aureus, adjunctive antibiotic therapy, rifampicin resistance, hepatotoxicity, drug-drug interactions, survival, hepatitis C, risk-benefit assessment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Drug Interactions, Endocarditis, Bacterial, Female, Heart Valve Diseases, Humans, Liver, Male, Middle Aged, Retrospective Studies, Rifampin, Staphylococcal Infections, Staphylococcus aureus, Cohort Studies, Bacteremia, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.